These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9358199)

  • 1. Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol.
    Komura T; Takahara K; Sugano M; Fujinishi A; Tasaki H; Nakashima Y; Kuroiwa A
    Eur J Drug Metab Pharmacokinet; 1997; 22(3):201-6. PubMed ID: 9358199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in serum lipids and lipoproteins in 3 cases of heterozygous familial hypercholesterolemia treated by LDL apheresis on dextran sulfate-cellulose columns].
    Delplanque B; Emmerich J; Norol F; Jourdan D; Duedari N; Jacotot B
    Ann Med Interne (Paris); 1988; 139 Suppl 1():80-2. PubMed ID: 2470282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The first results demonstrating efficiency and safety of a double-column whole blood method of LDL-apheresis.
    Hequet O; Le QH; Rigal D; Mekhloufi F; Jaeger S; Sassolas A; Groisne L; Moulin P
    Transfus Apher Sci; 2010 Feb; 42(1):3-10. PubMed ID: 19932056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
    Dachet C; Jacotot B; Buxtorf JC
    Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis.
    Uauy R; Zwiener RJ; Phillips MJ; Petruska ML; Bilheimer DW
    J Pediatr; 1992 Jun; 120(6):892-8. PubMed ID: 1593349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia.
    Rubba P; Faccenda F; Di Somma S; Gnasso A; Scarpato N; Iannuzzi A; Nappi G; Postiglione A; De Divitiis O; Mancini M
    Stroke; 1993 Aug; 24(8):1154-61. PubMed ID: 8342189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.
    Empen K; Otto C; Brödl UC; Parhofer KG
    J Clin Apher; 2002; 17(1):38-43. PubMed ID: 11948705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia.
    Moriarty P; Sosland R; Gibson C; Belmont J
    Ther Apher Dial; 2010 Feb; 14(1):74-8. PubMed ID: 20438521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Endo M; Kusakabe N; Tanioka T; Kato H; Shoji T
    Atherosclerosis; 2006 May; 186(1):126-31. PubMed ID: 16043185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
    Shiina Y; Homma Y; Oguma T; Fusegawa Y; Ozawa H; Handa S; Tanabe T
    Tokai J Exp Clin Med; 2005 Sep; 30(3):149-55. PubMed ID: 16285605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia.
    Linseisen J; Wilhelm M; Hoffmann J; Hailer S; Keller C; Wolfram G
    Eur J Med Res; 1999 Oct; 4(10):433-41. PubMed ID: 10527957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood antioxidants (vitamin E and beta-carotene) in long-term low density lipoprotein apheresis.
    Assogba U; Lepage S; Bruckert E; Bonnefont-Rousselot D; Dairou F; de Gennes JL; Delattre J
    Clin Chim Acta; 1995 Mar; 235(2):147-57. PubMed ID: 7554269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
    Saku K; Takeda Y; Jimi S; Okabe M; Shirai K; Nii T; Naito S; Arakawa K
    J Cardiol; 1998 Apr; 31(4):239-45. PubMed ID: 9594373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol.
    Lappegård KT; Enebakk T; Thunhaug H; Hovland A
    Atherosclerosis; 2016 Aug; 251():119-123. PubMed ID: 27318831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective and semiselective low-density lipoprotein apheresis in familial hypercholesterolemia.
    Busnach G; Cappelleri A; Vaccarino V; Franceschini G; Dal Col A; Perrino ML; Brando B; Sirtori C; Minetti L
    Blood Purif; 1988; 6(3):156-61. PubMed ID: 3395475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum lipoprotein (a) levels during treatment with LDL apheresis for homozygous familial hypercholesterolemia].
    Lasunción MA; Teruel JL; Alvarez JJ; Gómez-Coronado D; Ortuño J; Herrera E
    Med Clin (Barc); 1992 Oct; 99(14):541-4. PubMed ID: 1434990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of LDL apheresis on blood rheology in two patients with homozygous familial hypercholesterolaemia.
    Fadul JE; Sandhagen B; Linde T; Vessby B; Wikström B; Danielson BG
    Blood Purif; 1997; 15(3):182-7. PubMed ID: 9262844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe hypercholesterolemia by LDL-apheresis: cholesterol-lowering effect and clinical evaluation.
    Saito Y; Shinomiya M; Shirai K; Yoshida S
    Beitr Infusionsther; 1988; 23():160-71. PubMed ID: 2484772
    [No Abstract]   [Full Text] [Related]  

  • 20. HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia.
    Zanetti M; Zenti M; Barazzoni R; Zardi F; Semolic A; Messa MG; Mearelli F; Russi G; Fonda M; Scarano L; Bonora E; Cattin L
    PLoS One; 2014; 9(7):e101290. PubMed ID: 25014007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.